GAITHERSBURG, Md., Oct. 11, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two ...

Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works. Those headwinds included the difficulties it faced in ...

(Reuters) -Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda, ...

Novavax was close to going under. In early 2023, it warned investors that it might not have enough funds to finish the year. However, the biotech has made significant changes over the past 18 months.

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 79.1% year on year to $139.5 million. Its GAAP loss of $0.06 per share was ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...